Review Article
Adjuvant Treatment of Melanoma
Table 14
Systematic data review.
| SP (%; 95% credible interval) | | Month 6 | Month 12 | Month 24 | Month 36 | Month 48 | Median OS |
| DTIC | 60.9 (58.5–63.2) | 36.3 (33.6–39.2) | 12.1 (9.3–15.4) | 3.7 (01.09–06.03) | 1.0 (0.2–2.7) | 11.0 (10–12.2) | DTIC + IFN | 60.9 (53.9–67.2) | 36.9 (29.6–44.5) | 13.5 (7.3–21.7) | 4.9 (1–12.7) | NA | 11.5 (9.2–15.4) | DTIC non IFN | 59.7 (50.3–67) | 35.6 (26.4–43.9) | 12.7 (6.8–20) | 4.6 (1.1–11) | 1.7 (0.1–7) | 11.2 (8.7–14.5) | DTIC + Oblimersen | 64.2 (58.4–70.5) | 41.2 (34.9–48) | 16.8 (11.3–23.2) | NA | NA | 12.9 (10.8–16) | TMZ | 64.8 (60.1–69.5) | 39.5 (34.2–44.9) | 11.9 (7.3–17.5) | 2.5 (0.5–6.8) | NA | 11.3 (9.8–13.2) | TMZ + IFN | 67.6 (59.4–75.2) | 43.6 (34.4–53.3) | 15.2 (8–24.5) | 4.0 (0.6–11.9) | NA | 12.5 (10.1–16.1) | TMZ non IFN | 69.6 (61.1–78.4) | 45.5 (34.9–56.8) | 15.0 (6.4–27) | NA | NA | 12.6 (9.9–17.1) | DTIC + IPI | 70.2 (63.8–75.3) | 48.4 (40.7–55.1) | 21.3 (14.8–28.7) | 8.5 (3.6–15.6) | 3.1 (0.5–9.2) | 14.7 (12.2–18.1) |
|
|